New Product Launch: NXtec D002 Hereditary Cancer Panel 2 for Broad Hereditary Cancer Analysis
We are pleased to announce the release of NXtec D002 Hereditary Cancer Panel 2, the latest addition to MRC Holland's digitalMLPA portfolio.
Building on the established NXtec D001 Hereditary Cancer Panel 1, the expanded NXtec D002 Hereditary Cancer Panel 2 contains probes detecting CNVs in 28 additional genes (56 in total) and 3 new variants (8 in total). This results in double the genomic coverage (compared to D001), enabling more comprehensive analysis of genes associated with germline cancers.
NXtec D002 Hereditary Cancer Panel 2 targets genes associated with a broad range of cancer types, such as neurofibromatoses, retinoblastoma, Wilms’ tumour, and many others, while retaining all the coverage of D001 which targets genes associated with 8 common cancer types – breast, ovarian, colorectal, gastric, prostate, pancreatic or endometrial cancer, and melanoma.
Launch offer
To celebrate the release of NXtec D002 Hereditary Cancer Panel 2, we are offering a 40% discount, exclusively for first-time digitalMLPA users, valid until December 31st, 2025. Contact us for more information and to receive your personal quote.
Key features
-
Expanded genomic coverage with 56 genes and 8 selected variants targeted
-
Reliable and specific CNV detection with reduced chance of incidental findings
-
Minimal DNA input (only 20 ng)
-
Fast turnaround (48–72 hours)
-
Free, easy-to-use analysis software
Check out the NXtec D002 Hereditary Cancer Panel 2 coverage
